ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has disclosed upcoming details about their presentation of Phase II trial results for ABBV-RGX-314, an investigational gene therapy for wet age-related macular degeneration (AMD (NASDAQ:AMD)). The data will be presented at the Hawaiian Eye and Retina 2024 Meeting, which is scheduled to take place from January 13-19 in Maui, HI.
The treatment, ABBV-RGX-314, is being developed in collaboration with AbbVie (NYSE:ABBV) and utilizes a one-time suprachoroidal delivery method to address wet AMD, diabetic retinopathy, and other chronic retinal conditions. The Phase II AAVIATE® study's results will be presented by John D. Pitcher, III, M.D., from Eye Associates of New Mexico, on Tuesday, January 16, 2024, at 2:47 p.m. EST.
REGENXBIO is a clinical-stage biotechnology company with a focus on gene therapy. The company's NAV Technology Platform includes exclusive rights to a portfolio of over 100 novel AAV vectors.
This announcement is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.